Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Learn Mem ; 24(1): 55-58, 2017 01.
Article in English | MEDLINE | ID: mdl-27980076

ABSTRACT

Distinguishing threatening from nonthreatening stimuli is essential for survival and stimulus generalization is a hallmark of anxiety disorders. While auditory threat learning produces long-lasting plasticity in primary auditory cortex (Au1), it is not clear whether such Au1 plasticity regulates memory specificity or generalization. We used muscimol infusions in rats to show that discriminatory threat learning requires Au1 activity specifically during memory acquisition and retrieval, but not during consolidation. Memory specificity was similarly disrupted by infusion of PKMζ inhibitor peptide (ZIP) during memory storage. Our findings show that Au1 is required at critical memory phases and suggest that Au1 plasticity enables stimulus discrimination.


Subject(s)
Auditory Cortex/physiology , Conditioning, Classical/physiology , Fear/physiology , Memory/physiology , Analysis of Variance , Animals , Auditory Cortex/drug effects , Conditioning, Classical/drug effects , Discrimination, Psychological/drug effects , Discrimination, Psychological/physiology , Enzyme Inhibitors/pharmacology , Fear/drug effects , GABA-A Receptor Agonists/pharmacology , Memory/drug effects , Muscimol/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Rats
2.
Neuropsychopharmacology ; 40(4): 938-46, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25288485

ABSTRACT

Nicotinic acetylcholine receptor (nAChR) blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some treatment-resistant patients; however, it is not known whether these effects are independent, or whether the two neurotransmitter systems act synergistically. We first determined that the SSRI fluoxetine and the nicotinic partial agonist cytisine have synergistic effects in a mouse model of antidepressant efficacy, whereas serotonin depletion blocked the effects of cytisine. Using a pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepressant-like effects of cytisine, suggesting that this subtype might mediate the interaction between the serotonergic and cholinergic systems. The 5-HT1A receptors are located both presynaptically and postsynaptically. We therefore knocked down 5-HT1A receptors in either the dorsal raphe (presynaptic autoreceptors) or the hippocampus (a brain area with high expression of 5-HT1A heteroreceptors sensitive to cholinergic effects on affective behaviors). Knockdown of 5-HT1A receptors in hippocampus, but not dorsal raphe, significantly decreased the antidepressant-like effect of cytisine. This study suggests that serotonin signaling through postsynaptic 5-HT1A receptors in the hippocampus is critical for the antidepressant-like effects of a cholinergic drug and begins to elucidate the molecular mechanisms underlying interactions between the serotonergic and cholinergic systems related to mood disorders.


Subject(s)
Alkaloids/therapeutic use , Antidepressive Agents/therapeutic use , Gene Expression Regulation , Hippocampus/drug effects , Receptor, Serotonin, 5-HT1A/metabolism , Stress, Psychological , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Animals , Azocines/therapeutic use , Disease Models, Animal , Drug Synergism , Fluoxetine/therapeutic use , Gene Expression Regulation/drug effects , HEK293 Cells , Hindlimb Suspension , Hippocampus/metabolism , Humans , Interpersonal Relations , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Quinolizines/therapeutic use , Receptor, Serotonin, 5-HT1A/genetics , Serotonin Receptor Agonists/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Stress, Psychological/drug therapy , Stress, Psychological/etiology , Stress, Psychological/pathology
3.
Proc Natl Acad Sci U S A ; 110(50): 20260-5, 2013 Dec 10.
Article in English | MEDLINE | ID: mdl-24277819

ABSTRACT

Survival in a dangerous environment requires learning about stimuli that predict harm. Although recent work has focused on the amygdala as the locus of aversive memory formation, the hypothalamus has long been implicated in emotional regulation, and the hypothalamic neuropeptide orexin (hypocretin) is involved in anxiety states and arousal. Nevertheless, little is known about the role of orexin in aversive memory formation. Using a combination of behavioral pharmacology, slice physiology, and optogenetic techniques, we show that orexin acts upstream of the amygdala via the noradrenergic locus coeruleus to enable threat (fear) learning, specifically during the aversive event. Our results are consistent with clinical studies linking orexin levels to aversive learning and anxiety in humans and dysregulation of the orexin system may contribute to the etiology of fear and anxiety disorders.


Subject(s)
Amygdala/physiology , Fear , Intracellular Signaling Peptides and Proteins/metabolism , Learning/physiology , Locus Coeruleus/physiology , Neuropeptides/metabolism , Acoustic Stimulation , Animals , Benzoxazoles/administration & dosage , Benzoxazoles/pharmacology , Channelrhodopsins , Conditioning, Classical , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Male , Naphthyridines , Neuropeptides/antagonists & inhibitors , Optogenetics , Orexins , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , Urea/administration & dosage , Urea/analogs & derivatives , Urea/pharmacology
4.
Proc Natl Acad Sci U S A ; 110(9): 3573-8, 2013 Feb 26.
Article in English | MEDLINE | ID: mdl-23401542

ABSTRACT

Symptoms of depression can be induced in humans through blockade of acetylcholinesterase (AChE) whereas antidepressant-like effects can be produced in animal models and some clinical trials by limiting activity of acetylcholine (ACh) receptors. Thus, ACh signaling could contribute to the etiology of mood regulation. To test this hypothesis, we administered the AChE inhibitor physostigmine to mice and demonstrated an increase in anxiety- and depression-like behaviors that was reversed by administration of nicotinic or muscarinic antagonists. The behavioral effects of physostigmine were also reversed by administration of the selective serotonin reuptake inhibitor fluoxetine. Administration of fluoxetine also increased AChE activity throughout the brain, with the greatest change in the hippocampus. To determine whether cholinergic signaling in the hippocampus could contribute to the systemic effects of cholinergic drugs, we infused physostigmine or virally delivered shRNAs targeting AChE into the hippocampus. Both pharmacological and molecular genetic decreases in hippocampal AChE activity increased anxiety- and depression-like behaviors and decreased resilience to repeated stress in a social defeat paradigm. The behavioral changes due to shRNA-mediated knockdown of AChE were rescued by coinfusion of an shRNA-resistant AChE transgene into the hippocampus and reversed by systemic administration of fluoxetine. These data demonstrate that ACh signaling in the hippocampus promotes behaviors related to anxiety and depression. The sensitivity of these effects to fluoxetine suggests that shRNA-mediated knockdown of hippocampal AChE represents a model for anxiety- and depression-like phenotypes. Furthermore, abnormalities in the cholinergic system may be critical for the etiology of mood disorders and could represent an endophenotype of depression.


Subject(s)
Anxiety/psychology , Cholinergic Neurons/metabolism , Depression/psychology , Hippocampus/metabolism , Resilience, Psychological , Signal Transduction , Stress, Psychological/metabolism , Acetylcholinesterase/metabolism , Animals , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Anxiety/complications , Anxiety/drug therapy , Anxiety/metabolism , Behavior, Animal/drug effects , Cholinergic Antagonists/pharmacology , Cholinergic Antagonists/therapeutic use , Cholinergic Neurons/drug effects , Cholinergic Neurons/pathology , Dependovirus/metabolism , Depression/complications , Depression/drug therapy , Depression/metabolism , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Gene Knockdown Techniques , Hindlimb Suspension , Hippocampus/drug effects , Hippocampus/pathology , Humans , Male , Mice , Mice, Inbred C57BL , Phenotype , Physostigmine , RNA, Small Interfering/metabolism , Receptors, Cholinergic/metabolism , Signal Transduction/drug effects , Stress, Psychological/complications , Stress, Psychological/drug therapy , Time Factors
5.
Neurochem Int ; 61(2): 266-76, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22561101

ABSTRACT

Dopamine D1 receptor (D1R) ligands may directly interact with the NMDA receptor (NMDAR), but detailed knowledge about this effect is lacking. Here we identify D1R ligands that directly modulate NMDARs and examine the contributions of NR2A and NR2B subunits to these interactions. Binding of the open channel blocker [(3)H]MK-801 in membrane preparations from rat- and mouse brain was used as a biochemical measure of the functional state of the NMDAR channel. We show that both D1R agonist A-68930 and dopamine receptor D2 antagonist haloperidol can decrease [(3)H]MK-801 binding with increased potency in membranes from the NR2A(-/-) mice (i.e. in membranes containing NR2B only), as compared to the inhibition obtained in wild-type membranes. Further, a wide range of D1R agonists such as A-68930, SKF-83959, SKF-83822, SKF-38393 and dihydrexidine were able to decrease [(3)H]MK-801 binding, all showing half maximal inhibitory concentrations ~20 µM, and with significant effects occurring at or above 1 µM. With membranes from D1R(-/-) mice, we demonstrate that these effects occurred through a D1R-independent mechanism. Our results demonstrate that dopamine receptor ligands can selectively influence NR2B containing NMDARs, and we characterize direct inhibitory NMDAR effects by different D1R ligands.


Subject(s)
Brain/metabolism , Dizocilpine Maleate/metabolism , Excitatory Amino Acid Antagonists/metabolism , Receptors, Dopamine/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , Benzazepines/metabolism , Binding, Competitive/drug effects , Blotting, Western , Dopamine Antagonists/metabolism , Dopamine Plasma Membrane Transport Proteins/metabolism , In Vitro Techniques , Ligands , Male , Membranes/metabolism , Mice , Rats , Rats, Inbred WKY , Receptors, Dopamine/drug effects , Receptors, Dopamine D1/biosynthesis , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Second Messenger Systems/drug effects , Signal Transduction/drug effects
6.
Neurochem Int ; 59(7): 1074-81, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21924313

ABSTRACT

The effects of the fungal neurotoxin penitrem A on the GABAergic and glutamatergic systems in rat brain were evaluated. Penitrem A inhibited binding of the GABA(A)-receptor ligand [³H]TBOB to rat forebrain and cerebellar membrane preparations with IC50 (half maximal inhibitory concentration) values of 11 and 9 µM, respectively. Furthermore, penitrem A caused a concentration-dependent increase of [³H]flunitrazepam and [³H]muscimol binding in rat forebrain, but not in cerebellar preparations. The stimulation of [³H]flunitrazepam binding by penitrem A was abolished by the addition of GABA. In cerebellar preparations, a different pharmacological profile was found, with penitrem A allosterically inhibiting [³H]TBOB binding by interacting with a bicuculline-sensitive site. Moreover, penitrem A inhibited the high affinity uptake of GABA and glutamate into cerebellar synaptosomes with IC50 values of 20 and 47 µM, respectively. The toxin showed no effect on NMDA or AMPA glutamate receptor binding. In conclusion, our results suggest that penitrem A exerts region-specific effects in the brain, leading to positive modulation of GABA(A)-receptor function in forebrain. Conversely, penitrem A may act as a bicuculline-like convulsant in cerebellum.


Subject(s)
Mycotoxins/pharmacology , Tremor/chemically induced , gamma-Aminobutyric Acid/metabolism , Animals , Male , Rats , Rats, Wistar , Tremor/metabolism
7.
J Neurochem ; 119(1): 240-50, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21824140

ABSTRACT

The spontaneously hypertensive rat (SHR) is widely used as a model of attention-deficit/hyperactivity disorder (ADHD). Deficits in central nicotinic receptors (nAChRs) have been previously observed in SHRs, which is interesting since epidemiological studies have identified an association between smoking and ADHD symptoms in humans. Here, we examine whether nAChR deficits in SHRs compared with Wistar Kyoto rat (WKY) controls are nAChR subtype-specific and whether these deficits correlate with changes at the level of mRNA transcription in specific brain regions. Levels of binding sites (B(max) ) and dissociation constants (K(d)) for nAChRs were determined from saturation curves of high-affinity [³H]epibatidine- and [³H] Methyllycaconitine (MLA) binding to membranes from cortex, striatum, hippocampus and cerebellum. In additional brain regions, nAChRs were examined by autoradiography with [¹²5I]A-85380 and [¹²5I]α-bungarotoxin. Levels of mRNA encoding nAChR subunits were measured using quantitative real-time PCR (qPCR). We showed that the number of α4ß2 nAChR binding sites is lower globally in the SHR brain compared with WKY in the absence of significant differences in mRNA levels, with the exception of lower α4 mRNA in cerebellum of SHR compared with WKY. Furthermore, nAChR deficits were subtype- specific because no strain difference was found in α7 nAChR binding or α7 mRNA levels. Our results suggest that the lower α4ß2 nAChR number in SHR compared with WKY may be a consequence of dysfunctional post-transcriptional regulation of nAChRs.


Subject(s)
Attention Deficit Disorder with Hyperactivity/genetics , Attention Deficit Disorder with Hyperactivity/psychology , RNA, Messenger/genetics , Receptors, Nicotinic/genetics , Aconitine/analogs & derivatives , Aconitine/metabolism , Animals , Azetidines/metabolism , Brain Chemistry/genetics , Brain Chemistry/physiology , Bridged Bicyclo Compounds, Heterocyclic/metabolism , Bungarotoxins/metabolism , In Vitro Techniques , Kinetics , Male , Membranes/drug effects , Membranes/metabolism , Nicotinic Agonists/metabolism , Nicotinic Antagonists/metabolism , Protein Processing, Post-Translational/genetics , Protein Processing, Post-Translational/physiology , Pyridines/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Receptors, Nicotinic/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Thermodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...